PD-L1 anticorps

N° du produit ABIN6944458

L’anticorps Lapin Monoclonal anti-PD-L1 a été validé pour WB et FACS. Il convient pour détecter PD-L1 dans des échantillons de Humain.

Aperçu rapide pour PD-L1 anticorps (ABIN6944458)

Antigène: PD-L1 (CD274 (PD-L1))

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-L1 est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS)

Clone: 6C8

Détail du produit anti-PD-L1 anticorps

Réactivité croisée: Humain

Purification: Purified by Protein A.

Immunogène: Recombinant human PD-L1 extracellular domain

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
FCM 1:20-100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur PD-L1

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: PD-L1

Sujet:

Synonyms: Programmed cell death 1 ligand 1, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed death ligand 1

Background: Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).

ID gène: 29126

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints